Cancer healthcare professionals—doctors, nurses, psychologists, and social workers—show openness to psychedelic-assisted therapy for advanced cancer patients, driven by a desire to alleviate suffering and a lack of effective current treatments. However, this openness is tempered by concerns about patient safety and the need for rigorous, well-designed trials. The study identified four themes: beneficence (alleviating suffering), non-maleficence (keeping vulnerable patients safe), viewing psychedelic-assisted therapy as a transformative approach with real potential, and recognizing that new frontiers carry risks. These findings offer a foundation for engaging healthcare professionals in future research and clinical applications.
Cancer health-care practitioners in New Zealand and the USA perceive psychedelic-assisted therapy as potentially beneficial for cancer patients, especially those with advanced disease no longer receiving curative treatment. They consider research in this area important and express willingness to refer patients to trials, though they emphasize that work should incorporate spiritual and indigenous perspectives of health. US practitioners had greater awareness of psychedelics, while New Zealand practitioners more strongly believed that spiritual and indigenous factors should be considered. The findings suggest that practitioners may be more open to studies beginning in palliative and end-of-life contexts.